MDMariana Deboni

Mariana Deboni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Deboni has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Upper and small bowel Crohn's disease in Brazilian children: Phenotypic characteristic and surgical risk

    by Jane Oba, Carlos Walter Sobrado, Elizete Aparecida Lomazi, Mariana Deboni, Michela Cynthia da Rocha Marmo, Vanessa Adriana Scheeffer, Silvio da Rocha Carvalho, Adérson Omar Mourão Cintra Damião, Matheus Freitas Cardoso de Azevedo, Carlos Frederico Sparapan Marques, et al.

    Objectives: Upper and small bowel Crohn's disease (U‐SBCD) represents a clinically aggressive phenotype with high complication rates yet remains diagnostically challenging. In low‐ and middle‐income countries (LMICs), limited inflammatory bowel disease (IBD) awareness contributes to diagnostic delays, but their impact on U‐SBCD outcomes remains poorly characterized. We aimed to characterize clinical features, management patterns, and surgical outcomes of pediatric U‐SBCD in Brazil, establishing IBD baseline for future regional comparisons in LMIC setting. Methods: This multicenter retrospective study analyzed 124 pediatric Crohn′s disease (CD) patients (diagnosed < 18 years) from six Brazilian centers according to revised PORTO‐European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) criteria. Patients with U‐SBCD (Paris L4a/L4b, n = 39) were compared to non‐SBCD (L1/L2/L3). Univariate and multivariable analyses assessed demographics, diagnostic delay, disease behavior, growth impairment, and therapeutic outcomes over 18 months follow‐up. The population comprised predominantly African–Brazilian admixture. Results: U‐SBCD patients presented at older age (median 14 vs. 12 years; p = 0.001) with greater height impairment ( p = 0.010) and lower body mass index (BMI)/age z ‐scores (−1.14 vs. −0.44; p = 0.029). Severe weight loss ( z ‐score < −2) conferred 8.3‐fold increased U‐SBCD odds (95% confidence interval [CI]: 2.17–31.66; p = 0.002). Each year of diagnostic delay increased U‐SBCD odds by 22% (95% CI: 1.06–1.39; p = 0.004). U‐SBCD patients required more biologic therapy (97% vs. 75%; p = 0.003) with higher treatment escalation rates (31.6% vs. 21.2%; p = 0.004). Multivariate analysis confirmed U‐SBCD as an independent three‐fold predictor of surgery (OR 3.02; 95% CI: 1.02–8.94; p = 0.046). A 9‐year‐old girl with U‐SBCD died perioperatively. Psychiatric symptoms affected 30% of both groups. Conclusion: In LMIC settings, strengthening medical education is essential to improve early recognition of U‐SBCD and prevent progression to irreversible complications. Notably, the phenotypic pattern observed in our study more closely resembled that reported in Asian pediatric patients than Caucasian cohorts.

  • Open Access

    HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH REDUCTION IN SCHOOL AND WORK PRODUCTIVITY RATHER THAN PHYSICAL IMPAIRMENT: A MULTIDISCIPLINARY STUDY

    by Jane Oba, Carlos W Sobrado, Aderson O M C Damião, Matheus Azevedo, Alexandre Carlos, Natália Queiroz, Claudio A Len, Ricardo K Toma, Mariana Deboni, Marcos J Ozaki, et al.

    BACKGROUND: Inflammatory bowel diseases (IBD), comprising Crohn’s disease and ulcerative colitis, are chronic inflammatory diseases of the gastrointestinal tract that often have their onset among adolescents and young adults (AYA). IBD are characterized by episodes of active disease interspersed with periods of remission, and its activity is inversely correlated with health-related quality of life (HRQL). OBJECTIVE: This study aimed to determine whether AYA in remission or with low IBD activity would exhibit HRQL similar to that of age-matched healthy individuals, and whether demographic and disease factors could affect HRQL using a ‘patient-reported outcome’ instrument. METHODS: This study enrolled only AYA with IBD, with low activity. This research included five multidisciplinary clinics of two academic hospitals: Paediatric Gastroenterology, Gastroenterology, Coloproctology, Paediatric Rheumatology and Adolescent divisions, São Paulo, Brazil. A total of 59 AYA with IBD (age, 13-25 years) and 60 healthy AYA (age, 13-25 years) completed the Pediatric Quality of Life Inventory 4.0 and 36-Item Short-Form Health Survey questionnaires and the visual analogue scale (VAS) for pain. Demographic data, extra-intestinal manifestations, treatment, and outcomes regarding CD and UC were evaluated. RESULTS: AYA with IBD and healthy controls were similar with respect to median ages (18.63 [13.14-25.80] years vs 20.5 [13.68-25.84] years, P=0.598), proportion of female sex (42% vs 38%, P=0.654), and percentage of upper middle/middle Brazilian socioeconomic classes (94% vs 97%, P=0.596). The school/work score was significantly lower in AYA with IBD than in healthy controls (70 [10-100] vs 75 [5-100], P=0.037). The ‘general health-perception’ score was significantly lower in AYA with IBD than in healthy controls (50 [10-80] vs 0 [25-90], P=0.0002). The median VAS, FACES pain rating scale, and total VAS scores were similar between the two groups (2 [0-10] vs 3 [0-9], P=0.214). No association between HRQL and clinical and demographic parameters was identified among IBD patients. CONCLUSION: AYA with low IBD activity reported poor HRQL in school/work and general health perception domains, which highlights a disability criterion in this vulnerable population.